Telomere Stack
79
协同作用
2
10,500
intermediate
May 17, 2026
概述
The Telomere Stack is a focused two-peptide protocol targeting chromosomal maintenance and cellular rejuvenation. Epithalon''s primary mechanism is activation of the catalytic subunit of telomerase (hTERT), the enzyme responsible for adding TTAGGG repeats to chromosome ends. In cell culture studies, Epithalon-treated fibroblasts showed a 33% increase in telomere length and extended their replicative lifespan by approximately 10 additional cell divisions beyond the Hayflick limit. In Khavinson''s longitudinal human studies, elderly patients receiving Epithalon showed normalized melatonin production, improved immune markers, and reduced all-cause mortality compared to controls over 6-12 year follow-up periods. GHK-Cu contributes to this stack through its remarkable gene expression modulation profile. Genome-wide studies reveal that GHK-Cu resets expression of numerous aging-related genes toward youthful patterns, including genes involved in DNA repair (GADD45A, XRCC1), antioxidant defense (SOD3, glutathione peroxidase), and anti-inflammatory pathways (IL-6 suppression, TGF-beta modulation). This transcriptomic "resetting" effect complements Epithalon''s telomere maintenance by ensuring that cells with preserved telomere length also maintain youthful functional capacity rather than persisting in a senescent-adjacent state. The stack follows a cyclical protocol: Epithalon is administered daily for 10 days, then discontinued for 4-6 months while GHK-Cu continues daily. This cycling is based on Khavinson''s research showing that telomerase activation occurs during the treatment window and persists for months afterward, making continuous administration unnecessary. GHK-Cu provides ongoing cellular maintenance between Epithalon cycles. This is one of the more conservative longevity stacks, suitable for individuals who want to address cellular aging biomarkers with well-characterized peptides.
给药方案
10,000 mcg
每剂
500 mcg
每剂
目标与证据
警告
- Epithalon was removed from the FDA Category 2 list (April 2026) but remains pending PCAC review (July 24, 2026) — not legal to compound yet. Telomere extension claims based on in-vitro and animal studies. Human longevity data is observational only.
Comments
Sign in to join the discussion
免责声明: 此堆栈由社区提交,仅供研究用途。Peptide Contacts不对提交的堆栈的安全性或有效性进行验证。使用任何肽类协议前,请务必咨询合格的医疗专业人员。